Real-world application of surufatinib in the treatment of neuroendocrine tumors: a multi-center retrospective study in China.

ABSTRACT: Recently, the incidence of neuroendocrine tumors (NETs), characterized by neuroendocrine differentiation, has increased. Their heterogeneous origins and biological behaviors complicate diagnosis and treatment. Surufatinib, a novel oral tyrosine kinase inhibitor with dual anti-angiogenic and immunomodulatory properties, has shown promising efficacy against NETs in recent clinical trials. However, comparative data on the prognostic impact of surufatinib treatment remain limited. We investigated risk factors associated with mortality and tumor progression in patients with NETs, and aimed to provide insights into the administration of surufatinib to improve the clinical outcomes of these patients. In this multi-center, observational study, we retrospectively analyzed 373 patients diagnosed wit

SUBMITTER: Gao X 

PROVIDER: S-EPMC12802006 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature